JorgeMChavesMD

Oncology • Tacoma, WA

Physician

Join to view full profile

Dr. Chaves is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chaves' full profile

Already have an account?

Office
1624 South I Street
Suite 102
Tacoma, WA 98405
Phone+1 253-383-3366

Fax+1 253-383-3376

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Boston University Medical CenterResidency, Internal Medicine, 2005 - 2008
McGovern Medical School at UTHealthClass of 2005

Certifications & Licensure

WA State Medical License 2011 - 2025
CT State Medical License 2010 - 2011

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

Phase 1 Study of ONT-10 in Patients With Solid Tumors Start of enrollment: 2013 Mar 01
Completed
Phase 1
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 1
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Start of enrollment: 2014 Feb 28
Completed
Phase 1
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Start of enrollment: 2013 Dec 31
Completed
Phase 1
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142) Start of enrollment: 2016 Feb 03
Terminated
Phase 1, Phase 2
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers Start of enrollment: 2016 Sep 30
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D.
Richard Kim, Mustapha Tehfe, Petr Kavan, Jorge Chaves, Jeremy S Kortmansky
Clinical Colorectal Cancer. 2024-06-01
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E.
Eric X Chen, Petr Kavan, Mustapha Tehfe, Jeremy S Kortmansky, Michael B Sawyer
Clinical Colorectal Cancer. 2024-06-01
51 citations
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and...
Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, Do-Youn Oh, Diana L Hanna
The Lancet. Oncology. 2022-12-01

Abstracts/Posters

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Jorge M. Chaves, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019